——The 2021 China (Taizhou) Pharmaceutical Summit was successfully concluded
As a normal activity of China (Taizhou) International Pharmaceutical Expo, on October 24, the annual conference of China (Taizhou) Pharmaceutical Summit was successfully concluded.
The summit was co-sponsored by Taizhou Pharmaceutical High-tech Zone and the Biotechnology and Pharmacy Working Committee of the China Peasants' and Workers' Democratic Party, and hosted by the Organizing Committee of the China (Taizhou) Pharmaceutical Summit and the Taizhou Municipal Committee of the Peasants' and Workers' Democratic Party. The summit invited 12 authoritative experts in the field of biomedicine and traditional Chinese medicine culture, including Academician Yu Mengsun, an expert in aviation medicine and biomedical engineering, and Zhang Xueshi, president of Harbin Medical University, to discuss the two major themes of "biomedical research and development and scientific research and innovation under the new crown epidemic" and "development and cultural dissemination of traditional Chinese medicine industry". Zhao Qun, Qiu Mingyue, Wang Zhenghong, Cai Guobin, Huang Lihong, Wu Yupu, Ma Xinsheng, Zhou Zhenghai and other leading experts, Representative Zhang Xia of the Hong Kong Trade Development Council Jiangsu And other enterprise representatives, as well as more than 40 national, industry and local party media attended the meeting.
Tang Chengkui, deputy secretary of the Taizhou Municipal Party Committee, delivered a speech
The summit was presided over by Yang Zhe, former inspector of the Department of Major Special Projects of the Ministry of Science and Technology, and Zuo Jianping, director of the Biotechnology and Pharmacy Work Committee of the Chinese Peasants' and Workers' Democratic Party and researcher of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. Tang Chengkui, deputy secretary of the Taizhou Municipal Party Committee, Fan Haihong, first-class inspector and deputy director of the Jiangsu Provincial Regional Cooperation and Exchange Association and former Jiangsu Provincial Development and Reform Commission, Liu Jinghui, executive deputy secretary general of the summit organizing committee, Li Junde, former vice president and secretary general of the Chinese Association of Traditional Chinese Medicine, Hu Xiaomeng, former deputy director of the Supervision Center of the National Health Commission and first-class inspector, and Wu Lan, secretary of the party committee of Inner Mongolia Medical University, delivered speeches respectively. Academician Liu Liang, honorary president of Macau University of Science and Technology and director of the State Key Laboratory of Quality Research in Chinese Medicines, also sent a letter to the organizing committee, expressing regret that he could not attend the summit and wishing the conference a complete success.
Yang Zhe, a first-level inspector of the major special project department of the former Ministry of Science and Technology, presided over the presidency
Tang Chengkui, deputy secretary of the Taizhou Municipal Party Committee, said in his speech that since the establishment of the China Taizhou Pharmaceutical Summit in 2016, more than 30 academicians of the two academies and Nobel Prize winners have been invited to exchanges, and academic achievements have become an important reference for decision-making of relevant state departments, and the summit has gradually become a high-end academic platform for the industry with high popularity and greater influence in China. This summit focuses on the two themes of "biomedical research and development and scientific research and innovation under the new crown epidemic" and "development and cultural dissemination of traditional Chinese medicine industry", which not only meets the practical needs of the normalization of epidemic prevention and control, but also helps to promote the high-quality development of the traditional Chinese medicine industry. He hoped that the organizing committee of the summit would further exert its academic advantages, serve the development of Taizhou's pharmaceutical industry, and make more contributions to building a strong public health system and safeguarding people's health.
Innovation: Forging a sharp spear shield against the epidemic
Xia Ningshao, director of the National Infectious Disease Diagnostic Reagent and Vaccine Engineering Technology Research Center of Xiamen University, believes in the report "Research on Protective Immunity Induced by Nasal Spray Vaccine" that the advantages of the nasal spray vaccine they developed are painless, rapid onset, long-lasting protection, and broad-spectrum antiviral, which can meet the needs of rapid emergency response, increase the immune barrier for close and sub-close contacts, and improve the rapid control ability of china's punctate outbreaks.
Li Jia, director of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, believes in the report "Accelerating the Transformation of China's New Drug Research and Development from Imitation Innovation to Original Innovation" that in the next five to ten years, the global pharmaceutical industry will change from heavy imitation innovation to heavy original innovation, and only by always adhering to scientific and technological innovation, independent innovation, and firmly mastering the core technology in their own hands can the core competitiveness of pharmaceutical companies be realized. Zhu Tao, chief scientist of Tianjin Kangxino Biology, gave a speech on the topic of "Challenges and Innovations of Adenoviral Vector New Crown Vaccine", and he said that the inhalation vaccine developed by Kangxino Biologics is based on "atomized drug delivery". The results of the research show that the best way to boost immunization should be inhaled vaccines, which may become a trend in the future.
Li Jiazuo, director of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, gave a report
Jiang Shibo, director of the Institute of Pathogenic Microbiology of Fudan University, believes in the report "Research and Development of Efficient Broad-spectrum Anti-Coronavirus Drugs and Vaccines" that the independent research and development of efficient and broad-spectrum anti-novel coronavirus drugs is a major event that China needs to work hard at present. Not long ago, the EK1 atomizer developed by the Fudan-Jinbo Functional Protein Joint Research Center is about to enter clinical trials, which means that the new coronavirus broad-spectrum drug independently developed by China in the near future is expected to be listed. Yan Jinghua, a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, introduced the research work she and her team are engaged in with "COVID-19 Monoclonal Antibody Treatment Strategy": First, single-cell sequencing human antibodies, human antibodies are to block the binding of RBD and ACE2, prevent the virus from entering the cell, and in clinical experiments and rhesus monkey experiments, it is safe and effective. In addition, the mouse-derived ACE2 antibody is humanized, which shows its effectiveness and safety in vivo and in vitro, and the synergistic neutralization effect of CB6 and h11A11 antibodies can effectively control the escape of the virus.
The scene of the forum on "Biomedical R&D and Scientific Research and Innovation under the Covid-19 Epidemic"
BuRen Batu, Secretary of the Party Committee of the Affiliated Hospital of Inner Mongolia University for Nationalities, "Research on the Clinical and Mechanism of Mongolian Medicine in the Treatment of New Coronavirus", believes that Mongolian medicine and traditional Chinese medicine are the crystallization of ancient Chinese philosophical thoughts, which have unique advantages in the treatment of epidemics and chronic diseases, and they are currently developing new products based on traditional Mongolian medicine. Jiangsu Shuoshi Biotechnology Co., Ltd. is the first company in China to develop molecular diagnostic reagents after the outbreak of the new crown epidemic, and General Manager Wang Guoqiang introduced the specific situation of Shuoshi biotechnology innovation and product research and development with the title of "Opportunities and Challenges for the Development of China's Molecular Diagnostic Industry under the New Crown Epidemic". He said that the new crown epidemic has accelerated the pace of our domestic diagnostic reagent companies going abroad, and after Shuoshi Bio increased international marketing in June last year, it has now established cooperative relations with more than 100 countries.
Inheritance: Contribute China's strength to human health
Academician Yu Mengsun, an expert in aviation medicine and biomedical engineering, believes in the report "Large-scale and Orderly Opening Up: The Only Strategy for People's Health" that realizing people's health is a huge and complex system engineering, and this system engineering must first blossom in the land of China, solve China's medical reform problems, and make pilots and models for the world. "Large-scale and orderly opening up" is a system project for the modernization of traditional Chinese medicine in the new era, and in the future, China will certainly be able to walk in the forefront of the world in terms of realizing human health in both theory and practice, so as to drive China's science and technology to walk in the forefront of the world in the future.
Academician Yu Mengsun, an expert in aeronautical medicine and biomedical engineering, made a report
Zhang Xueshi, president of Harbin Medical University, introduced in the report "The Story of Arsenic In the Treatment of Leukemia" that targeted treatment drugs for non-small cell lung cancer are a classic case in the era of precision medicine, but in fact, the most typical examples of tumor fields in precision medicine and precision treatment are provided by Chinese, which is the treatment of acute promyelocytosis. He believes that after the clinical demand rises to a scientific problem, this is the best way for medicine to come out of medicine. Finding clinical problems condensed into scientific problems is ability, quality, and ability. Scientific research based on and clinically oriented is the most vital.
Report by Professor Zhang Weidong, Deputy Dean of the School of Pharmacy of the Naval Military Medical University
Professor Zhang Weidong, Deputy Dean of the School of Pharmacy of the Naval Military Medical University, took the "Research on Chinese Medicine Musk Baoxin Pill" as an example in the report "Innovation Helps the High-quality Development of Traditional Chinese Medicine", and introduced in detail the research strategy of Traditional Chinese medicine prescription based on the holistic view proposed and established by them. He said that prescriptions are the main form of traditional Chinese medicine, so that doctors "believe in traditional Chinese medicine, use quasi-Traditional Chinese medicine, use high-quality Traditional Chinese medicine" is related to clinical safety and efficacy, and elucidating the pharmacodynamic substance basis of Traditional Chinese medicine compounding, analyzing its mechanism of action, ensuring drug quality, and clear clinical positioning have become the key bottlenecks in the sustainable development of China's traditional Chinese medicine industry. He believes that the modern Chinese medicine prescription research system should include basic research on pharmacodynamic substances, systematic biology research, standardization of the whole process of production chain, modern pharmacological research, network biology research, and international normative evidence-based medical research.
Professor Baolong of the School of Mongolian Medicine of Inner Mongolia University for Nationalities introduced the basic theories and basic knowledge of Mongolian medicine such as the history, current situation and clinical application of Mongolian medicine. Liu Bin, executive deputy director of the Cyberspace Administration of Nanjing Municipality, elaborated on how the media can better serve the excavation, inheritance and dissemination of Chinese medicine culture and better contribute to the development strategy of Chinese medicine with the title of "Media Responsibility in the Dissemination of Chinese Medicine Culture".
During the meeting, the organizing committee of the summit held a closed-door meeting on "Traditional Chinese Medicine Technology Innovation and Immunity Enhancement", inviting Professor Wang Zhenghong, doctoral supervisor of the Air Force Medical University, front-line clinical experts such as Taizhou People's Hospital and Taizhou Municipal Hospital of Traditional Chinese Medicine, and Liu Xiaogang, chairman of Shangai Technology, to discuss the traditional moxibustion technology innovation and clinical application.
Cooperation: Cooperate to promote the dissemination of Chinese medicine culture
After the outbreak of the new crown pneumonia epidemic, the unique role of traditional Chinese medicine in the process of treating patients has attracted great attention at home and abroad. Chinese medicine is not only the traditional Chinese medical ideas and technologies for curing diseases and saving people, but also the concentrated embodiment of the essence of traditional Chinese culture, its ideological concepts and practical methods contain profound Chinese philosophical wisdom, inheriting and promoting the traditional Chinese medicine culture, not only can lay a deep cultural foundation for the revitalization of traditional Chinese medicine, but also can more deeply understand the essence of China's excellent traditional culture and firmly establish cultural self-confidence.
Zuo Jianping, director of the Biotechnology and Pharmacy Working Committee of the Chinese Peasants' and Workers' Democratic Party and researcher of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, presided over the forum on the theme of traditional Chinese medicine
The 2021 China (Taizhou) Pharmaceutical Summit invited academicians and experts, social organizations, media, enterprises, culture and other guests in the direction of traditional Chinese medicine to participate in the forum, and invited inner Mongolia, Henan, Sichuan, Jilin and other ethnic medicine representative cities and local medicinal material production bases of traditional Chinese medicine to discuss the development of the traditional Chinese medicine industry and cultural dissemination. Wu Lan, Secretary of the Party Committee of Inner Mongolia Medical University, congratulated the conference through video, and Delin, deputy director of the Tongliao City Traditional Chinese Medicine Industry Development Office, led more than 10 Mongolian medical experts to attend the meeting.
Li Junde, former vice president and secretary general of the Chinese Association of Traditional Chinese Medicine, delivered a speech
During the forum, the organizing committee of the summit signed a strategic cooperation agreement with the Jiangsu Regional Cooperation and Exchange Association, the Xilingol League of Inner Mongolia, and the relevant units and departments of Tongliao City, aiming to better help the development of the Traditional Chinese medicine industry and cultural communication through media dissemination and regional cooperation.
The Organizing Committee of the Summit signed a strategic cooperation agreement with the Jiangsu Regional Cooperation and Exchange Association
The participants also reached a consensus on the joint development of a cultural communication platform for traditional Chinese medicine (ethnic medicine). (Photo by Li Hao, Qian Li)